ArticleDiabetes2012
Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice.
Article in Diabetes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 1 synthesis or guideline pooled it, 223 citations in OpenAlex.
- Pooled it
- Urine miRNAs: potential biomarkers for monitoring progression of early stages of diabetic nephropathy.Medical hypotheses · 2013Trial
- Exercise reverses diabetes-induced microRNA dysregulation in white adipose tissue.Irish journal of medical science · 2026Article
- Cell-specific DNA methylation in human alpha and beta cells regulates gene expression in type 2 diabetes.Nature metabolism · 2026Article
- Therapeutic Potential of Holothuria leucospilota Extract in STZ-Induced Diabetic Rats: Targeting Inflammation and Apoptosis at the Gene Expression Level.Endocrinology, diabetes & metabolism · 2026Article
- Bioengineering and omics approaches for Type 1 diabetes practical research: advancements and constraints.Annals of medicine · 2025Review
- Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model.Annals of hepato-biliary-pancreatic surgery · 2025Article
- Comprehensive sequencing profile and functional analysis of IsomiRs in human pancreatic islets and beta cells.Diabetologia · 2025Article
- Exploring the link between environmental chemical exposures and epigenetic modifications in diabetes mellitus: A review.Biomolecules & biomedicine · 2025Review
- microRNAs in Type 1 Diabetes: Roles, Pathological Mechanisms, and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Thyroid dysfunction in Hashimoto's thyroiditis: a pilot study on the putative role of miR-29a and TGFβ1.Endocrine · 2024Article
- Advances in Theranostic Approaches and Emerging Biomarkers of Diabetes Mellitus.Diagnostics (Basel, Switzerland) · 2024Article
- Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes.Biomedicines · 2024Review
- Exosomes and Macrophages: Bidirectional Mutual Regulation in the Treatment of Diabetic Complications.Cellular and molecular bioengineering · 2024Review
- A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes.Cell reports. Medicine · 2024Article
- Influence of Different Glucose Concentrations on the Expression of miR-29c-3p microRNA in Mesenchymal Stem Cells.International journal of hematology-oncology and stem cell research · 2024Article
- Extracellular vesicles: mechanisms and prospects in type 2 diabetes and its complications.Frontiers in endocrinology · 2024Review
- Circulating hsa-miR-320a and its regulatory network in type 1 diabetes mellitus.Frontiers in immunology · 2024Article
- Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- A Review of micro RNAs changes in T2DM in animals and humans.Journal of diabetes · 2023Review
69 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the initial phases of type 1 diabetes, pancreatic islets are invaded by immune cells, exposing β-cells to proinflammatory cytokines. This unfavorable environment results in gene expression modifications leading to loss of β-cell functions. To study the contribution of microRNAs (miRNAs) in this process, we used microarray analysis to search for changes in miRNA expression in prediabetic NOD mice islets. We found that the levels of miR-29a/b/c increased in islets of NOD mice during the phases preceding diabetes manifestation and in isolated mouse and human islets exposed to proinflammatory cytokines. Overexpression of miR-29a/b/c in MIN6 and dissociated islet cells led to impairment in glucose-induced insulin secretion. Defective insulin release was associated with diminished expression of the transcription factor Onecut2, and a consequent rise of granuphilin, an inhibitor of β-cell exocytosis. Overexpression of miR-29a/b/c also promoted apoptosis by decreasing the level of the antiapoptotic protein Mcl1. Indeed, a decoy molecule selectively masking the miR-29 binding site on Mcl1 mRNA protected insulin-secreting cells from apoptosis triggered by miR-29 or cytokines. Taken together, our findings suggest that changes in the level of miR-29 family members contribute to cytokine-mediated β-cell dysfunction occurring during the initial phases of type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.